{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T01:14:36Z","timestamp":1776474876008,"version":"3.51.2"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s13555-020-00436-1","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T06:02:52Z","timestamp":1597903372000},"page":"1121-1135","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Real-World Evaluation of the Long-Term Safety and Efficacy of Infliximab in the Treatment Moderate-to-Severe Psoriasis"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7829-0026","authenticated-orcid":false,"given":"Emily K.","family":"Haque","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaminah","family":"Azhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Corbett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9108-5577","authenticated-orcid":false,"given":"Jillian","family":"Frieder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Menter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,20]]},"reference":[{"issue":"961","key":"436_CR1","first-page":"967.e5","volume":"72","author":"J Vanderpuye-Orgle","year":"2015","unstructured":"Vanderpuye-Orgle J, Zhao Y, Lu J, et al. Evaluating the economic burden of psoriasis in the united states. J Am Acad Dermatol. 2015;72(961):967.e5.","journal-title":"J Am Acad Dermatol"},{"key":"436_CR2","doi-asserted-by":"publisher","first-page":"e12771","DOI":"10.1111\/dth.12771","volume":"32","author":"SE Liang","year":"2019","unstructured":"Liang SE, Cohen JM, Ho RS. Psoriasis and suicidality: a review of the literature. Dermatol Ther. 2019;32:e12771.","journal-title":"Dermatol Ther"},{"key":"436_CR3","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1111\/jdv.14460","volume":"31","author":"J Koo","year":"2017","unstructured":"Koo J, Marangell LB, Nakamura M, et al. Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression. J Eur Acad Dermatol Venereol. 2017;31:1999\u20132009.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"436_CR4","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029\u201372.","journal-title":"J Am Acad Dermatol"},{"key":"436_CR5","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/ced.12841","volume":"41","author":"NJ Korman","year":"2016","unstructured":"Korman NJ, Zhao Y, Pike J, Roberts J. Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA. Clin Exp Dermatol. 2016;41:514\u201321.","journal-title":"Clin Exp Dermatol"},{"key":"436_CR6","first-page":"138","volume":"158","author":"B Kirby","year":"2008","unstructured":"Kirby B, Richards HL, Mason DL, Fortune DG, Main CJ, Griffiths CEM. Alcohol consumption and psychological distress in patients with psoriasis. Br J Dermatol. 2008;158:138\u201340.","journal-title":"Br J Dermatol"},{"key":"436_CR7","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/j.1365-2133.2010.09941.x","volume":"163","author":"K Abuabara","year":"2010","unstructured":"Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the UK. Br J Dermatol. 2010;163:586\u201392.","journal-title":"Br J Dermatol."},{"key":"436_CR8","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jaad.2006.08.040","volume":"55","author":"AL Neimann","year":"2006","unstructured":"Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55:829\u201335.","journal-title":"J Am Acad Dermatol"},{"key":"436_CR9","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1067\/mjd.2003.540","volume":"48","author":"DJ Najarian","year":"2003","unstructured":"Najarian DJ, Gottlieb AB. Connections between psoriasis and Crohn\u2019s disease. J Am Acad Dermatol. 2003;48:805\u201324.","journal-title":"J Am Acad Dermatol"},{"key":"436_CR10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jaad.2010.11.055","volume":"65","author":"A Menter","year":"2011","unstructured":"Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65:137\u201374.","journal-title":"J Am Acad Dermatol."},{"key":"436_CR11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s13555-018-0230-9","volume":"8","author":"J Carrascosa","year":"2018","unstructured":"Carrascosa J, Jacobs I, Petersel D, Strohal R. Biosimilar drugs for psoriasis: principles, present, and near future. Dermatol Ther. 2018;8:173\u201394.","journal-title":"Dermatol Ther"},{"key":"436_CR12","doi-asserted-by":"publisher","unstructured":"Shear N. INFLIXIMAB.  In: Shear N, editor. Litt\u2019s drug eruption & reaction manual 25E. CRC Press. 2019. p. 147\u20138. https:\/\/doi.org\/10.1201\/9780429020162.","DOI":"10.1201\/9780429020162"},{"key":"436_CR13","first-page":"247","volume":"17","author":"KA Papp","year":"2017","unstructured":"Papp KA, Lebwohl MG. Onset of action of biologics in patients with moderate-to-severe psoriasis. J Drugs Dermatol. 2017;17:247.","journal-title":"J Drugs Dermatol"},{"key":"436_CR14","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","volume":"366","author":"K Reich","year":"2005","unstructured":"Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366:1367\u201374.","journal-title":"Lancet"},{"key":"436_CR15","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","volume":"357","author":"U Chaudhari","year":"2001","unstructured":"Chaudhari U, Romano P, Mulcahy L, Dooley L, Baker D, Gottlieb A. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001;357:1842\u20137.","journal-title":"Lancet"},{"key":"436_CR16","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","volume":"51","author":"AB Gottlieb","year":"2004","unstructured":"Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51:534\u201342.","journal-title":"J Am Acad Dermatol"},{"key":"436_CR17","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1067\/mjd.2003.10","volume":"48","author":"AB Gottlieb","year":"2003","unstructured":"Gottlieb AB, Masuda S, Ramamurthi R, et al. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-\u03b1 monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol. 2003;48:68\u201375.","journal-title":"J Am Acad Dermatol"},{"key":"436_CR18","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1038\/jid.2013.78","volume":"133","author":"A Nast","year":"2013","unstructured":"Nast A, Sporbeck B, Rosumeck S, et al. Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action. J Clin Investig Dermatol. 2013;133:1963\u201370.","journal-title":"J Clin Investig Dermatol"},{"key":"436_CR19","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/art.20967","volume":"52","author":"CE Antoni","year":"2005","unstructured":"Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005;52:1227\u2013366.","journal-title":"Arthritis Rheum"},{"key":"436_CR20","doi-asserted-by":"publisher","first-page":"31.e1","DOI":"10.1016\/j.jaad.2006.07.017","volume":"56","author":"A Menter","year":"2007","unstructured":"Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56:31.e1\u201331.e15.","journal-title":"J Am Acad Dermatol."},{"key":"436_CR21","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1159\/000433528","volume":"231","author":"A Jacobi","year":"2015","unstructured":"Jacobi A, Langenbruch A, Purwins S, Augustin M, Radtke MA. Prevalence of obesity in patients with psoriasis: results of the national study PsoHealth3. Dermatology. 2015;231:231\u20138.","journal-title":"Dermatology"},{"key":"436_CR22","doi-asserted-by":"publisher","first-page":"7353420","DOI":"10.1155\/2019\/7353420","volume":"2019","author":"C Rodr\u00edguez-Cerdeira","year":"2019","unstructured":"Rodr\u00edguez-Cerdeira C, Cordeiro-Rodr\u00edguez M, Carnero-Gregorio M, et al. Biomarkers of inflammation in obesity-psoriatic patients. Mediat Inflamm. 2019;2019:7353420.","journal-title":"Mediat Inflamm."},{"key":"436_CR23","doi-asserted-by":"publisher","first-page":"R115","DOI":"10.1186\/ar3841","volume":"14","author":"S Ottaviani","year":"2012","unstructured":"Ottaviani S, Allanore Y, Tubach F, et al. Body mass index influences the response to infliximab in ankylosing spondylitis. Arthritis Res Ther. 2012;14:R115.","journal-title":"Arthritis Res Ther"},{"key":"436_CR24","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrgastro.2016.181","volume":"14","author":"S Singh","year":"2016","unstructured":"Singh S, Dulai PS, Zarrinpar A, Ramamoorthy S, Sandborn WJ. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol. 2016;14:110\u201321.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"436_CR25","doi-asserted-by":"publisher","first-page":"e0186575","DOI":"10.1371\/journal.pone.0186575","volume":"12","author":"F Scaldaferri","year":"2017","unstructured":"Scaldaferri F, D'Ambrosio D, Holleran G, et al. Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with infliximab. PLoS ONE. 2017;12:e0186575.","journal-title":"PLoS ONE"},{"key":"436_CR26","doi-asserted-by":"publisher","first-page":"e0195123","DOI":"10.1371\/journal.pone.0195123","volume":"13","author":"S Singh","year":"2018","unstructured":"Singh S, Facciorusso A, Singh AG, et al. Obesity and response to anti-tumor necrosis factor-\u03b1 agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis. PLoS ONE. 2018;13:e0195123.","journal-title":"PLoS ONE"},{"key":"436_CR27","doi-asserted-by":"publisher","first-page":"4422","DOI":"10.1016\/j.vaccine.2015.06.101","volume":"33","author":"SD Painter","year":"2015","unstructured":"Painter SD, Ovsyannikova IG, Poland GA. The weight of obesity on the human immune response to vaccination. Vaccine. 2015;33:4422\u20139.","journal-title":"Vaccine"},{"issue":"964","key":"436_CR28","first-page":"7","volume":"31","author":"M Crouch","year":"2017","unstructured":"Crouch M, Guesdon W, Shaikh S. Obesity suppresses B cell development and impairs antibody production upon antigen challenge. FASEB J. 2017;31(964):7.","journal-title":"FASEB J"},{"key":"436_CR29","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1093\/rheumatology\/kew326","volume":"55","author":"P H\u00f8jgaard","year":"2016","unstructured":"H\u00f8jgaard P, Glintborg B, Kristensen LE, Gudbjornsson B, Love TJ, Dreyer L. The influence of obesity on response to tumour necrosis factor-\u03b1 inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries. Rheumatology (Oxford). 2016;55:2191\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"436_CR30","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/j.1468-3083.2011.04065.x","volume":"25","author":"L Puig","year":"2011","unstructured":"Puig L. Obesity and psoriasis: Body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol. 2011;25:1007\u2013111.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"436_CR31","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1690623","author":"M Colls-Gonzalez","year":"2019","unstructured":"Colls-Gonzalez M, Notario-Rosa J, Bas-Minguet J, et al. Association between infliximab concentrations and clinical response in psoriasis: a prospective cohort study. J Dermatol Treat. 2019. https:\/\/doi.org\/10.1080\/09546634.2019.1690623.","journal-title":"J Dermatol Treat."},{"key":"436_CR32","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/bjd.12654","volume":"170","author":"L Hsu","year":"2014","unstructured":"Hsu L, Snodgrass BT, Armstrong AW. Antidrug antibodies in psoriasis: a systematic review. Br J Dermatol. 2014;170:261\u201373.","journal-title":"Br J Dermatol"},{"key":"436_CR33","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa020888","volume":"348","author":"F Baert","year":"2003","unstructured":"Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease. N Engl J Med. 2003;348:601\u20138.","journal-title":"N Engl J Med"},{"key":"436_CR34","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541\u20139.","journal-title":"Lancet"},{"key":"436_CR35","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/S1542-3565(04)00238-1","volume":"2","author":"SB Hanauer","year":"2004","unstructured":"Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2004;2:542\u201353.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"436_CR36","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","volume":"41","author":"RN Maini","year":"1998","unstructured":"Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor \u03b1 monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552\u2013633.","journal-title":"Arthritis Rheum"},{"key":"436_CR37","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1016\/S0016-5085(03)00382-2","volume":"124","author":"JMH Van den Brande","year":"2003","unstructured":"Van den Brande JMH, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn\u2019s disease. Gastroenterology. 2003;124:1774\u2013855.","journal-title":"Gastroenterology"},{"key":"436_CR38","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.clim.2005.01.007","volume":"115","author":"C Shen","year":"2005","unstructured":"Shen C, Maerten P, Geboes K, Van Assche G, Rutgeerts P, Ceuppens JL. Infliximab induces apoptosis of monocytes and T lymphocytes in a human\u2013mouse chimeric model. Clin Immunol. 2005;115:250\u20139.","journal-title":"Clin Immunol"},{"key":"436_CR39","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1053\/gast.2001.28702","volume":"121","author":"A L\u00fcgering","year":"2001","unstructured":"L\u00fcgering A, Schmidt M, L\u00fcgering N, Pauels H, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology. 2001;121:1145\u201357.","journal-title":"Gastroenterology"},{"key":"436_CR40","first-page":"723","volume-title":"Pharmacokinetic considerations in the treatment of inflammatory bowel disease","author":"M Schwab","year":"2001","unstructured":"Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Cham: Adis International; 2001. p. 723."}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-020-00436-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-020-00436-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-020-00436-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T23:09:01Z","timestamp":1629414541000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-020-00436-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["436"],"URL":"https:\/\/doi.org\/10.1007\/s13555-020-00436-1","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,20]]},"assertion":[{"value":"17 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}